Simple isocratic high-performance liquid chromatographic method for measurement of iodixanol in human plasma

Development and application of a liquid chromatography-mass spectrometry method for residual iodixanol quantification in AAV-based gene therapy product development

Adeno-associated viruses (AAVs) are non-enveloped viruses which have become popular gene transfer vectors to deliver DNA to target cells in clinical gene therapy. Iodixanol-based density gradient is one of the widely used purification methods for serotype-independent AAV. However, residual iodixanol in AAV could be a safety concern, and further purification to remove this process-related impurity is typically needed. An analytical assay with high sensitivity is essential for the detection of residual iodixanol to ensure the safety of AAV products. We developed a liquid chromatography-mass spectrometry (LC-MS) method with the limit of quantification (LOQ) of 0.01 μg/mL for residual iodixanol measurement in AAV. The method also demonstrated linearity over four orders of magnitude which allows quantifying a high iodixanol concentration in in-process samples with excellent recovery and accuracy. In addition, we further explored a highly efficient purification method for removal of the residual iodixanol, to minimize the safety concern from iodixanol as a process impurity.

Bioanalytical methods for iodixanol and their application to studies on metabolism and protein binding

The iodine-specific detection techniques X-ray fluorescence spectrometry, neutron activation analysis and radiochemical detections of (125)I-labelled substance are well suited for quantification of iodixanol in biological samples. The limit of detection is 60 microgram iodixanol/ml for X-ray fluorecence analysis and 1 to 10 microgram iodixanol/ml for neutron activation analysis. Reversed-phase high-performance liquid chromatography (HPLC) has been employed when selective determination of iodixanol was needed for identificational purposes or when quantification of very small amounts of iodixanol was essential. An optimized HPLC method for quantification of iodixanol in rat serum and urine is presented. The limit of detection for this method is 0.20 microgram iodixanol/ml for rat serum and 3.0 microgram iodixanol/ml for rat urine. When samples were analyzed by HPLC and thin layer chromatography, no metabolites of iodixanol were observed in rat, monkey or human urine, or in rat kidney and bile. Studies with equilibrium dialysis and HPLC determination of iodixanol showed no protein binding of the contrast agent in human plasma; the 95% confidence interval for the result was 0.0+/-2.1%.